Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulgent Genetics Inc (NQ: FLGT )

38.04 -1.59 (-4.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 248,471
Open 39.56
Bid (Size) 37.63 (1)
Ask (Size) 38.46 (1)
Prev. Close 39.63
Today's Range 37.92 - 39.63
52wk Range 28.27 - 65.17
Shares Outstanding 29,701,246
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist
Fulgent is moving past its pandemic-era business, and that's a good thing. 
Via The Motley Fool
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
From Fulgent Genetics, Inc.
Via Business Wire

Performance

YTD
+24.07%
+24.07%
1 Month
+8.10%
+8.10%
3 Month
+24.52%
+24.52%
6 Month
+11.62%
+11.62%
1 Year
-25.34%
-25.34%

More News

Read More
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Via The Motley Fool
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
Via The Motley Fool
Fulgent Genetics Earnings Perspective: Return On Capital Employed
Via Benzinga
Fulgent Genetics: Q1 Earnings Insights
Via Benzinga
Preview: Fulgent Genetics's Earnings
Via Benzinga
Looking Into Fulgent Genetics's Return On Capital Employed
Via Benzinga
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Fulgent Reports First Quarter 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
From Fulgent Genetics, Inc.
Via Business Wire
Earnings Scheduled For May 5, 2023
Via Benzinga
7 Stocks to Buy to Bag Big-Time Returns in Q2
Via InvestorPlace
Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
From Fulgent, Inc.
Via Business Wire
Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
From Fulgent Genetics, Inc.
Via Business Wire
NASDAQ:FLGT Long Term Investor Alert: Investigation of Potential Wrongdoing at Fulgent Genetics, Inc.
Via SBWire
FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – FLGT
From Scott+Scott Attorneys at Law LLP
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Fulgent Expands Board of Directors with Addition of Reggie Groves
From Fulgent Genetics, Inc.
Via Business Wire
Which Is the Better Buy: Vertex or Invitae?
Via The Motley Fool
My Top 7 Strong Conviction Buys for 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.